Annals of Surgical Oncology最新文献_第8页

ASO Author Reflections: Should We Resect the "Unresectable"? Since Alexis Carrel and Joseph G. Fortner, Almost 120 Years of (Pancreatic) Vascular Surgery in New York. ASO作者反思：我们是否应该切除“不可切除的”？自亚历克西斯·卡雷尔和约瑟夫·g·福特纳以来，纽约近120年的（胰腺）血管手术。

IF 3.4 2区医学

Annals of Surgical Oncology Pub Date : 2025-04-01 Epub Date: 2025-01-04 DOI: 10.1245/s10434-024-16826-0

Jonathan Garnier, Christopher L Wolfgang

引用次数: 0

ASO Author Reflections: What the Eye Cannot See. ASO作者反思：眼睛看不见的东西。

IF 3.4 2区医学

Annals of Surgical Oncology Pub Date : 2025-04-01 Epub Date: 2025-01-16 DOI: 10.1245/s10434-024-16862-w

Eleanor A Fallon, Michael G White

引用次数: 0

ASO Author Reflections: The Age-Old Question in Nipple-Sparing Mastectomy: Is Older Age a Contraindication?

IF 3.4 2区医学

Annals of Surgical Oncology Pub Date : 2025-04-01 Epub Date: 2025-01-23 DOI: 10.1245/s10434-024-16864-8

Abigail E Daly, Kyle J Anderman, Francys C Verdial

引用次数: 0

Prognostic Accuracy of ypTNM Stage in Patients with Pancreatic Cancer in the Era of Modern Neoadjuvant Therapy. 现代新辅助治疗时代胰腺癌患者ypTNM分期的预后准确性。

IF 3.4 2区医学

Annals of Surgical Oncology Pub Date : 2025-04-01 Epub Date: 2025-01-05 DOI: 10.1245/s10434-024-16792-7

Hyeong Seok Kim, Hochang Chae, Soo Yeun Lim, HyeJeong Jeong, So Jeong Yoon, Sang Hyun Shin, In Woong Han, Jin Seok Heo, Hongbeom Kim

{"title":"Prognostic Accuracy of ypTNM Stage in Patients with Pancreatic Cancer in the Era of Modern Neoadjuvant Therapy.","authors":"Hyeong Seok Kim, Hochang Chae, Soo Yeun Lim, HyeJeong Jeong, So Jeong Yoon, Sang Hyun Shin, In Woong Han, Jin Seok Heo, Hongbeom Kim","doi":"10.1245/s10434-024-16792-7","DOIUrl":"10.1245/s10434-024-16792-7","url":null,"abstract":"Background: The American Joint Committee on Cancer (AJCC) 8th edition TNM staging manual, which provided ypTNM for patients undergoing neoadjuvant therapy (NAT), has not been comparatively assessed against pTNM for prognosis in pancreatic cancer. This study aimed to compare the prognosis between ypTNM and pTNM stages.Patients and methods: Clinicopathological data from 586 patients who underwent pancreatic cancer surgery at a tertiary center between 2018 and 2022 were analyzed to compare survival outcomes between ypTNM and pTNM stages and identify prognostic factors.Results: The analysis included 541 patients (100 ypTNM, 441 pTNM). Significant differences in overall survival (OS) were observed among patients stratified by TNM stage (p < 0.001). However, no significant difference in OS was found between the ypTNM and pTNM groups (2-year survival rate (YSR): 76.8% vs. 66.7%, p = 0.094). Subgroup analysis by stage I (82.4% vs. 76.2%, p = 0.577) and II (68.8% vs. 61.6%, p = 0.715), and III (53.0% vs. 49.8%, p = 0.596) revealed similar survival rates. Multivariate analysis identified factors associated with OS: age > 65 years (HR 1.763, p < 0.001), CA19-9 > 150 U/mL (HR 1.439, p = 0.014), preoperative biliary drainage (HR 1.405, p = 0.029), pathologic T2 stage (HR 1.961, p = 0.004) and T3/4 stage (HR 2.830, p < 0.001) versus T0/1 stage, lymphovascular invasion (HR 2.220, p < 0.001), and adjuvant treatment (HR 0.251, p < 0.001).Conclusions: This study confirms comparable survival outcomes between ypTNM and pTNM stages in surgically resected pancreatic cancer, affirming the applicability of the TNM staging system after NAT. The results highlight the utility of TNM staging in guiding therapeutic decisions for patients undergoing NAT.","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2799-2808"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ASO Author Reflections: Complete Pathological Response after Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinomas-Curative Surgery in Cured Patients?

IF 3.4 2区医学

Annals of Surgical Oncology Pub Date : 2025-04-01 Epub Date: 2025-02-01 DOI: 10.1245/s10434-025-16925-6

Pietro Addeo, Milena Muzzolini, Christophe Laurent, Bruno Heyd, Alain Sauvanet, Jonathan Garnier, Marie Sophie Alfano, Sebastien Gaujoux, Charles De Ponthaud, Ugo Marchese, Doris Da Silva, Emmanuel Buc, Regis Souche, Jean Michel Fabre, Pierre-Emanuel Colombo, Lorenzo Ferre, Maxime Foguenne, Catherine Hubert, Mehdi El Amrani, Stephanie Truant, Lilian Schwartz, Nicolas Regenet, Aurelien Dupre, Raffaele Brustia, Rim Cherif, Julie Navez, Benjamin Darnis, Olivier Facy, Robin Grellet, Guillaume Piessen, Julie Veziant, Rami Rhaiem, Reza Kianmanesh, Elena Fernandez-De-Sevilla, Maximiliano Gelli, Abdelkader Taibi, Pauline Georges, Jean Yves Mabrut, Mickael Lesurtel, Alexandre Doussot, Philippe Bachellier

引用次数: 0

ASO Author Reflections: Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Early Recurrence and Patient-Tailored Management.

IF 3.4 2区医学

Annals of Surgical Oncology Pub Date : 2025-04-01 Epub Date: 2025-01-24 DOI: 10.1245/s10434-024-16810-8

Joseph R Habib, Ingmar F Rompen, Camila Hidalgo Salinas, Vincent P Groot, Ammar A Javed, Lois A Daamen

引用次数: 0

Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205). 由S-1和顺铂组成的新辅助放化疗用于临床可切除的4型或3型胃癌患者的I/II期研究（OGSG1205）。

IF 3.4 2区医学

Annals of Surgical Oncology Pub Date : 2025-04-01 Epub Date: 2025-01-15 DOI: 10.1245/s10434-024-16845-x

Masayuki Shinkai, Motohiro Imano, Masaki Yokokawa, Ryo Tanaka, Jin Matsuyama, Toshio Shimokawa, Hisato Kawakami, Taroh Satoh, Takushi Yasuda, Hiroshi Furukawa

{"title":"Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205).","authors":"Masayuki Shinkai, Motohiro Imano, Masaki Yokokawa, Ryo Tanaka, Jin Matsuyama, Toshio Shimokawa, Hisato Kawakami, Taroh Satoh, Takushi Yasuda, Hiroshi Furukawa","doi":"10.1245/s10434-024-16845-x","DOIUrl":"10.1245/s10434-024-16845-x","url":null,"abstract":"Background: To improve the prognosis of clinically resectable type 4 or large type 3 gastric cancer (GC), we performed a phase I/II study of neoadjuvant-radiotherapy combined with S-1 plus cisplatin.Patients and methods: Phase I, with a standard 3 + 3 dose-escalation design, was performed to define the recommended phase II dose. Efficacy and safety were evaluated in phase II. The three dose levels were as follows: level 0, S-1 60 mg/m2 on days 1-14 plus cisplatin 60 mg/m2 on day 1; level 1, S-1 80 mg/m2 on days 1-14 plus cisplatin 60 mg/m2 on day 1; and level 2, S-1 80 mg/m2 on days 1-14 and 22-35, plus cisplatin 60 mg/m2 on days 1 and 22. The starting dose was level 1. Radiotherapy was delivered at a total dose of 40 Gy in fractions for 4 weeks.Results: A total of six patients were enrolled in the phase I study. Dose-limiting toxicity was observed at level 2; level 1 was established as the recommended phase II dose. In phase II, 20 patients were enrolled from November 2012 to April 2018. Grade 3/4 leukopenia and nonhematologic adverse events occurred in 35% and 5% of the patients, respectively. In total, 19 patients underwent the protocol surgery; 2 (10.5%) achieved a pathological complete response. There were no treatment-related deaths; 3- and 5-year overall survival rates were 70.0 and 50.0%, respectively.Conclusions: Neoadjuvant chemoradiotherapy with S-1 plus cisplatin is a safe and promising treatment for clinically resectable type 4 or large type 3 GC.","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2651-2661"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ASO Author Reflections: Variation in Cost Centers Following Gastrointestinal Cancer Surgery. ASO作者反思：胃肠道肿瘤手术后成本中心的变化。

IF 3.4 2区医学

Annals of Surgical Oncology Pub Date : 2025-04-01 Epub Date: 2025-01-21 DOI: 10.1245/s10434-025-16934-5

Eshetu Worku, Mujtaba Khalil, Timothy M Pawlik

引用次数: 0

Stratified Impact of Therapies on Anaplastic Thyroid Cancer Outcomes in the Pre-Gene-Targeted Therapy Era.

IF 3.4 2区医学

Annals of Surgical Oncology Pub Date : 2025-04-01 Epub Date: 2025-01-27 DOI: 10.1245/s10434-024-16852-y

Kun Zhang, Xinyi Wang, Jianyong Lei, Anping Su, Tao Wei, Zhihui Li, Ya-Wen Chen

{"title":"Stratified Impact of Therapies on Anaplastic Thyroid Cancer Outcomes in the Pre-Gene-Targeted Therapy Era.","authors":"Kun Zhang, Xinyi Wang, Jianyong Lei, Anping Su, Tao Wei, Zhihui Li, Ya-Wen Chen","doi":"10.1245/s10434-024-16852-y","DOIUrl":"10.1245/s10434-024-16852-y","url":null,"abstract":"Background: Anaplastic thyroid cancer (ATC) is a highly lethal disease, often diagnosed with advanced locoregional and distant metastases, resulting in a median survival of just 3-5 months. This study determines the stratified effectiveness of baseline treatments in all combinations, enabling precise prognoses prediction and establishing benchmarks for advanced therapeutic options.Methods: The study extracted a cohort of pathologically confirmed ATC patients from the Surveillance, Epidemiology, and End Results program. Overall, 1879 patients from 2000 to 2018 were identified from the database. Kaplan-Meier survival curve estimation and Cox proportional hazard regression were applied.Results: Overall, compared with no treatment, surgery raised 1-year overall survival (OS) from 0.6% to 30% and median survival from <1 month to 3 months in ATC patients. For stage IVa, surgery increased 1-year OS from 21.5% to 71.8% and median survival from 2 to 23.5 months, and in stage IVb, surgery increased 1-year OS from 9.4% to 41.3% and median survival from 2 to 7 months; however, in stage IVc, the benefits of surgery were not markedly different from non-surgical approaches. When combined with surgery, other effective non-surgical ATC treatments demonstrated a surgery-dominant synergistic effect, particularly for stages IVa and IVb ATC, but not for stage IVc ATC.Conclusions: Our study provides insights into stratified baseline treatments for patients with ATC in all stages, emphasizing surgery's vital role in a multimodal approach.","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2732-2742"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143051337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ASO Visual Abstract: Blood Sample Collection in Randomized Controlled Trials for Biomarker Discovery and Validation: Experience of the PREOPANC-2 Trial.

IF 3.4 2区医学

Annals of Surgical Oncology Pub Date : 2025-04-01 DOI: 10.1245/s10434-025-17221-z

Esther N Dekker, Quisette P Janssen, Jacob L van Dam, Gaby J Strijk, Eva M M Verkolf, Sridhar Kandala, Jasper Dumas, Amine Fellah, Eileen M O'Reilly, Marc G H Besselink, Casper H J van Eijck, Marjolein Y V Homs, Geert-Jan van Tienhoven, Johanna W Wilmink, Dana A M Mustafa, Bas Groot Koerkamp

引用次数: 0